Stockwinners Market Radar for October 24, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:51 EDT Costco exec sells $1.41M in common stock - In a regulatory filing, Costco disclosed that its EVP Claudine Adamo sold 2,565 shares of common stock on October 23 in a total transaction size of $1.41M.

18:33 EDT Grifols' Araclon Biotech presents 'positive' results from Phase 2 ABvac40 study - The company states: "Araclon Biotech, a Grifols Group company dedicated to the research and development of therapies and diagnostic methods applied to neurodegenerative diseases, announced encouraging final results from its Phase 2 trial of ABvac40, an active vaccine against the Abeta40 peptide, for the treatment of patients with early-stage Alzheimer's disease. Araclon gave a late-breaking presentation at the 2023 Clinical Trials on Alzheimer's Disease conference. Results show that ABvac40 had a favorable safety profile, elicited a robust immune response against Abeta40, and demonstrated some potential cognitive benefits in early-stage AD patients, meeting primary endpoints and showing differences between the vaccine- and placebo-treated groups in some secondary exploratory endpoints. Data confirm preliminary findings indicating a comparable safety profile between ABvac40 and placebo groups, with similar rates of treatment-emergent adverse events. Specifically in the treatment group there were no reports of swelling or aseptic meningo-encephalo-myelitis, and few instances of micro-hemorrhages comparable to placebo and none leading to discontinuation. ABvac40 is uniquely designed to target the C-terminal end of the Abeta40 peptide, thus believed to prevent harmful reactions and avoid immune triggers responsible for meningoencephalitis, a complication observed in earlier AD vaccines. Emerging research suggests that undefinedbeta40 plays a role in cerebral amyloid angiopathy, a highly prevalent condition among the growing number of AD patients. According to estimates by the Alzheimer's Association, the number of patients with Alzheimer's disease is expected to double by the year 2050 in just the U.S., from 6.7 million in 2023."

18:29 EDT Opthea Ltd (ADR) trading halted, news pending

18:09 EDT Nexa Resources lowers Aripuana zinc production view to 20-23kt from 28-40kt - Nexa Resources provides an update on the progress of the Aripuana ramp-up phase and new estimates for production, in addition to exploration and project development and cash costs revisions. The figures contained in this report are considered preliminary and are unaudited. Aripuana: Zinc production for 2023 is now expected to be 20-23kt, lower than previous guidance of 28-40kt, mainly explained by processing plant limitations due to certain equipment resulting in a delayed ramp-up to expected steady production. For the same reasons, copper production is now expected to be 4-5kt instead of 6-8kt. 2023 production estimates for Nexa's other five mines remain unchanged. Cash Cost for the mining and smelting segments were revised downward by 29% to 35c to 38c per pound of zinc sold for mining, and 5% to $1.07 to $1.12 per pound of zinc sold for smelting, respectively, primarily due to higher by-products contribution and lower treatment charges positively impacting our mining segment. Exploration & Project Evaluation and Other expenses guidance are being reduced by $15M in 2023. This revision is mainly attributed to initiatives to optimize capital allocation. The capital expenditure required for the pump's replacement will not affect Capex guidance for 2023.

18:05 EDT Microsoft sees Q2 Gaming revenue growth mid-to-high 40% range - Sees Q2 operating expense $15.5B-$15.6B.

17:53 EDT Teledyne appoints Edwin Roks as CEO - The Board of Directors of Teledyne Technologies announced that Robert Mehrabian will be named Executive Chairman, effective January 1, 2024. As Executive Chairman, Mehrabian will remain actively involved with the company with a particular focus on strategy, technology, mergers and acquisitions and margin expansion programs. Mehrabian's employment contract has been amended and extended an additional three years to December 2026. In addition, Edwin Roks will assume the role of CEO and George C. Bobb III will assume the role of President and COO. Edwin Roks, current Executive Vice President of Teledyne, leads Teledyne's Digital Imaging Segment and has gained increasing levels of operational responsibility, including the successful integration of Teledyne's largest acquisitions. Roks joined Teledyne in 2011 with the acquisition of Teledyne DALSA and also served as Teledyne's CTO from 2014 to 2015. George C. Bobb III, current Executive Vice President of Teledyne, leads Teledyne's Aerospace and Defense Electronics Segment, the Marine Instrumentation group, the Engineered Systems Segment, and Teledyne Scientific & Imaging, which includes classified Digital Imaging programs, as well as Teledyne's Information Technology function. Jason VanWees, Vice Chairman, will continue in his current role, with responsibility for strategy, capital allocation, mergers & acquisitions, investor relations and margin improvement programs. Finally, Melanie S. Cibik, will be promoted to Executive Vice President, General Counsel, Chief Compliance Officer and Secretary, and will continue to oversee Teledyne's legal, compliance, human resources, ethics and corporate governance programs. VanWees and Miss Cibik joined Teledyne in connection with its spinoff in 1999. Bobb will report to Roks, effective January 1, 2024. VanWees will continue to report to Mehrabian. Miss Cibik will report to Roks and Mehrabian, as appropriate.

17:31 EDT Black Hills Wyoming files settlement pact for rate review in Wyoming - Black Hills Corp. announced that its Wyoming natural gas utility, Black Hills Wyoming Gas, LLC, doing business as Black Hills Energy, filed a settlement agreement for approval by the Wyoming Public Service Commission for its application for new rates to recover over $140M of investments since 2019 in its more than 6,400-mile natural gas system. "These critical investments support the long-standing expectations from our customers and communities for reliable, safe and resilient natural gas service, particularly during extreme weather, like Wyoming has experienced the last two winters," said Linn Evans, president and CEO of Black Hills Corp. "These investments are also needed to meet the growing needs of our Wyoming communities." The settlement agreement is pending a final hearing and approval by the Wyoming commission. If approved, the settlement agreement will generate approximately $13.9M of new annual revenues based on a capital structure of 51% equity and 49% debt and a return on equity of 9.85%. The agreement provides for new rates effective Jan. 1, 2024. The settlement agreement extends the Wyoming Integrity Rider for an additional four years of investments in the company's distribution, transmission, and storage integrity programs, limited to a maximum of $80M in project expenditures over that period. The agreement also approves the establishment of the Green Forward Program, a voluntary renewable natural gas environmental attribute and carbon offset pilot program.

17:25 EDT Alphabet says YouTube saw solid momentum in both ads, subscription services - Says heard positive feedback from partners at NFL on new features of NFL Sunday Ticket. Says pleased with growth and engagement on YouTube Shorts. Says Shorts has 70B daily views. Says solid growth in retail vertical. Comments taken from Q3 earnings conference call.

17:13 EDT Visa authorizes $25B buyback program - In October, Visa board of directors authorized a new $25.0 billion multi-year class A common stock share repurchase program.

17:03 EDT Waste Management sees sustainability growth capital spending $750M in 2023

17:01 EDT Rollins raises quarterly dividend from 13c per share to 15c - The dividend is payable December 11, 2023 to shareholders of record at the close of business on November 10, 2023. This represents an increase of 15 percent from the same quarter a year ago.

16:50 EDT Range Resources sees FY23 all-in capital budget $570M-$615M - Range is targeting a maintenance program in 2023, resulting in approximately flat production at 2.12-2.16 Bcfe per day, with ~30% attributed to liquids production. Range's 2023 all-in capital budget is $570M-$615M. Updated FY23 expense guidance include: Direct operating expense 11c-13c per mcfe; transportation, gathering, processing and compression expense $1.43-$1.46 per mcfe; taxes other than income 4c-5c per mcfe; exploration expense $22M-$28M; G&A expense 17c-19c per mcfe; interest expense 14c-16c per mcfe; DD&A expense 46c-48c per mcfe; net brokered gas marketing expense $0M-$5M.

16:43 EDT Mueller Water increases quarterly dividend 4.9% to 6.4c per share - Mueller Water announced that its board of directors has declared an increase to the company's quarterly dividend by approximately 4.9% to 6.4c per share from 6.1c per share, payable on or about November 20 to stockholders of record as of the close of business on November 9.

16:37 EDT Robert Half says Q3 gross margins remained strong due to pricing discipline - Says "operating cost base also benefited from the targeted actions we have taken to align costs with revenues." Says "confident" in growth prospects as macro landscape improves. Says "macroeconomic forecasts are mixed and this is reflected in clients' continued hiring caution. Clients are budget-sensitive and very selective in their hiring activities, including the approval of new projects." Comments taken from investor presentation slides.

16:34 EDT Quanterix launches p-Tau 217 blood biomarker test to aid Alzheimer's diagnosis - Lucent Diagnostics, a diagnostics brand of Quanterix, announced expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer's disease - LucentAD p-Tau 217. This lab developed test marks a major advance in the performance of scalable immunoassay-based blood biomarker tests intended for assessing amyloid pathology in individuals with memory complaints. p-Tau 217 has emerged as a top performing biomarker for Alzheimer's pathology, enabling clinical sensitivity and specificity in blood. Traditional methods include positron emission tomography or lumbar puncture for cerebrospinal fluid biomarkers, which are expensive, invasive, and lack wide availability. The recent approval of new therapies has highlighted an urgent need for improved diagnostic methods. Highly sensitive and specific blood-based biomarker tests have the potential to speed diagnosis and expand access to treatments for millions of individuals with early Alzheimer's disease.

16:34 EDT Novo Integrated Sciences board approves $5M stock repurchase program - Novo Integrated Sciences announced the Company's Board of Directors has approved the repurchase of up to $5 million of the Company's outstanding common stock from time to time in the open market at prevailing market prices or in privately negotiated transactions. Pending receipt of funds from the unsecured 15-year $70,000,000 promissory note with RC Consulting LLC in favor of SCP Tourbillion Monaco for a lump sum debt funding of $57,000,000, less fees and expenses, the amount and timing of any shares repurchased under the program will be determined at the discretion of management and will depend on a number of factors, including the market price of the Company's stock, trading volume, general market and economic conditions, the Company's capital position, legal requirements, and other factors. The repurchase program does not obligate the Company to acquire any particular number of shares, and the repurchase program may be discontinued at any time at the Company's discretion. Robert Mattacchione, Novo's CEO and Chairman of the Board, stated, "Today's announcement conveys our ongoing confidence in our business and dedication to enhancing stockholder value. This stock repurchase program is a direct reflection of our belief that our shares are undervalued, and a demonstration of our confidence in the business and the long-term opportunity ahead."

16:33 EDT Energy Recovery names David Moon interim CEO - Energy Recovery announced Mr. David Moon, a current member of the Energy Recovery Board of Directors, has been appointed interim Chief Executive Officer, effective immediately. Mr. Bob Mao will remain a member of the Board, and Ms. Pamela Tondreau, current Lead Independent Director, has been elected as the new Chairperson of the Board. A comprehensive search process to identify a permanent President and Chief Executive Officer, which includes internal and external candidates, has been underway with the assistance of a leading executive search firm. "The Board has firm conviction in Energy Recovery's long-term potential and is confident Mr. Moon is the right leader for this moment of transition, alongside the rest of the management team," said Ms. Tondreau. "The Board will work closely with the management team to ensure this transition is seamless for Energy Recovery's shareholders, customers, employees, and suppliers."

16:32 EDT Hepsiburada announces finalization of class actions, former CCO Buyumez leaves - Hepsiburada announced the finalization of the class actions and changes to its executive management team...As disclosed previously, the Company was a defendant in dual-track class action lawsuits, namely, the action filed on September 28 with the lead plaintiff IWA-Forest Industry Pension Plan, before the United States District Court, Southern District of New York under the case no: 1:21-cv-08634-PKC ; and the action filed on October 21, 2021, before the State Court under the case no. 655701/2021 . The Company had reached a settlement with the Plaintiffs of both the Federal Action and the State Action , subject to an approval and/or entry of judgment of the respective courts regarding the stipulation of the Settlement. The Federal Action was finally concluded on August 1, 2023 with the order and final judgment of the Federal Court approving the settlement. The Company announces that on September 22, 2023 the State Action is dismissed by the State Court with prejudice and the appeal period regarding the State Action has now expired. As a result, both the Federal Action and the State Action have been finally resolved without admission of any wrongdoing. Company's former Chief Commercial Officer CCO Mr. Murat Buyumez, who had taken a leave of absence, has decided to step down from his position effective October 20 . Mr. Ender Ozgun will continue to serve under the title of the CCO. The marketing department previously reporting to the CCO is reorganized to report to the Chief Executive Officer.

16:29 EDT NextPlay Technologies receives noncompliance letter from Nasdaq - NextPlay Technologies announced that the company received a notification letter from the Listing Qualifications Department of Nasdaq stating that because they have not received the company's quarterly report on Form 10-Q for the fiscal quarter ended August 31, the company remains noncompliant with Nasdaq Listing Rule 5250. The notification further provides the company until November 2 to submit an update to the plan to regain compliance previously submitted to and accepted by Nasdaq, and states that any additional staff exception that may be provided to the company to allow the company to regain compliance with all delinquent filings will be limited to November 27.

16:20 EDT Kodiak Gas Services announces first quarterly dividend of 38c - Kodiak Gas Services announced that its board of directors has declared Kodiak's first quarterly cash dividend of 38c per share of common stock, or $1.52 per share of common stock on an annualized basis, for the Q3. This cash dividend will be paid on November 10 to all stockholders of record as of the close of business on November 3.

16:18 EDT Matador sees Q4 average daily production 144,000-146,500 BOE per day - Matador began 2023 operating seven drilling rigs in the Delaware Basin. Following the closing of the Advance acquisition on April 12, 2023, Matador continued operating the drilling rig that Advance had been operating. In June 2023, Matador released this eighth operated drilling rig and continued operating seven drilling rigs in the Delaware Basin. Matador plans to operate seven drilling rigs for the remainder of 2023 and add back an eighth drilling rig in the first quarter of 2024. At October 24, 2023, Matador expects D/C/E capital expenditures for the fourth quarter of 2023 will be approximately $259 million, which is a 13% decrease as compared to $296 million for the third quarter of 2023 due to the mix of wells drilled and completed during the fourth quarter as compared to the third quarter. Matador expects its proportionate share of midstream capital expenditures to be approximately $87 million in the fourth quarter of 2023, as compared to $41.7 million in the third quarter of 2023 due to the timing of projects.

16:17 EDT Canadian National announces additional C$500M for normal course issuer bid - In January, CN announced the board's approval for a new normal course issuer bid permitting CN to purchase for cancellation, over a 12-month period, up to 32M common shares. The board has now approved an additional C$500 million, increasing the budget from approximately C$4B to approximately C$4.5B.

16:17 EDT SunPower to restate financial results after finding material weakness - In a regulatory filing, SunPower said that on October 19, the Audit Committee, based upon the recommendation of management, determined that the company's (i) audited financial statements included in the company's Annual Report on Form 10-K for the period ended January 1, 2023, filed with the U.S. SEC on March 10, 2023, (ii) unaudited financial statements included in the company's Quarterly Report on Form 10-Q for the quarterly period ended April 2, 2023, filed with the SEC on May 3, 2023, and (iii) unaudited financial statements included in the company's Quarterly Report on Form 10-Q for the quarterly period ended July 2, 2023, filed with the SEC on August 2, 2023, as well as the relevant portions of any communication which describe or are based on such financial statements, should no longer be relied upon. The company plans to restate, as soon as practicable, the financial statements for the Affected Periods in amendments to the Form 10-K, the Q1 2023 Form 10-Q, and the Q2 2023 Form 10-Q, respectively. In connection with the preparation of the financial statements, the company preliminarily determined that the value of consignment inventory of microinverter components at certain third-party locations had been overstated in the Affected Periods in the range of approximately $16M-$20M, resulting in the associated cost of revenue being understated. At this time, the company has not fully completed its review, and the expected financial impact of the errors described above is preliminary and subject to change. Additionally, the company is correcting other immaterial errors in the Affected Periods. Upon evaluation of the impact to Affected Periods, the company's management has concluded that in light of the matters, a material weakness exists in the company's internal control over financial reporting.

16:15 EDT Waste Connections reduced 14% greenhouse gas emissions from last year - Waste Connections released its 2023 Sustainability Report highlighting the Company's progress towards its long-term, aspirational sustainability targets. Achievements include a 14% year-over-year reduction in greenhouse gas emissions and a doubling of the Company's targeted improvement. In addition, the Company reaffirmed its commitment to invest approximately $200M in renewable natural gas, or RNG, facilities expected on line by 2026. Reduced Emissions and Increased Targeted Reductions: Reduced Scope 1 and 2 emissions by 14% in 2022 and achieved 27% reduction in emissions intensity on robust 2022 revenue growth; expanded emissions reduction commitment to 30% and initiated process for alignment of emissions reduction targets with SBT.

16:14 EDT Alphabet says took $86M charges in Q3 for workforce reductions - Alphabet said: "In January 2023, we announced a reduction of our workforce, and as a result we recorded employee severance and related charges of $86M and $2.1B for the three and nine months ended September 30, 2023, respectively. In addition, we are taking actions to optimize our global office space. As a result, exit charges recorded during the three and nine months ended September 30, 2023 were $16M and $649M, respectively. In addition to these exit charges, for the three and nine months ended September 30, 2023, we incurred $207M in accelerated rent and accelerated depreciation. We may incur additional charges in the future as we further evaluate our real estate needs."

16:13 EDT Snap jumps 11% to nearly $11 after reporting Q3 results

16:13 EDT Alphabet CFO says fundamental strength 'apparent again' in Q3 - Ruth Porat, President and Chief Investment Officer; CFO said: "The fundamental strength of our business was apparent again in Q3, with $77 billion in revenue, up 11% year over year, driven by meaningful growth in Search and YouTube, and momentum in Cloud. We continue to focus on judicious capital allocation to deliver sustainable financial value."

16:12 EDT Visa reports Q4 payments volume up 9% - The company states: "Payments volume for the three months ended September 30, 2023 increased 9% over the prior year on a constant-dollar basis. Cross-border volume excluding transactions within Europe, which drives our international transaction revenues, increased 18% on a constant-dollar basis for the three months ended September 30, 2023. Total cross-border volume on a constant-dollar basis increased 16% in the quarter. Total processed transactions, which represent transactions processed by Visa, for the three months ended September 30, 2023, were 56.0 billion, a 10% increase over the prior year."

16:08 EDT Talkspace names Nikole Benders-Hadi CMO - Talkspace announced the appointment of Nikole Benders-Hadi, MD, as Chief Medical Officer. In this role, Dr. Benders-Hadi will lead Talkspace's clinical practice, partnering with providers to deliver the highest quality digital mental health care as Talkspace continues to grow and scale. "Dr. Benders-Hadi's extensive background in psychiatry and her experience in working within integrated health systems to make mental health care more accessible align perfectly with Talkspace's mission," said Jon Cohen, MD, CEO of Talkspace. "Her dedication to reducing stigma and improving access to care, combined with her track record of leadership in healthcare, makes her an invaluable addition to our team. We look forward to leveraging her expertise to continue leading the way in providing greater access to high-quality mental health care for all."

16:06 EDT Getty Realty increases quarterly dividend 4.7% to 45c per share - Getty Realty announced that its Board of Directors declared a cash dividend of 45c per common share, an increase of 4.7% over the previous quarterly dividend. The dividend is payable on January 11, 2024 to holders of record on December 28, 2023.

16:06 EDT Wolfspeed names Thomas Werner as new Board Chair - Wolfspeed announced that Thomas Werner, a board member since 2006, has been elected the new Chairman of the Board, effective immediately. Werner succeeds Darren Jackson, who stepped down as chair after five years in the role. Jackson will continue to serve as a member of the Wolfspeed Board. In addition, Board Member Stacy Smith will replace John Replogle as the Chair of the Governance and Nominations Committee.

16:05 EDT UMB Financial raises quarterly dividend 2.6% to 39c per share - The cash dividend will be payable on January 2, 2024, to shareholders of record at the close of business on December 11, 2023.

16:04 EDT Microsoft 'rapidly infusing AI across every layer of the tech stack,' says CEO - "With copilots, we are making the age of AI real for people and businesses everywhere," said Satya Nadella, chairman and CEO of Microsoft. "We are rapidly infusing AI across every layer of the tech stack and for every role and business process to drive productivity gains for our customers."

16:03 EDT Microsoft reports Q1 Cloud revenue $31.8B - Reports Q1 Productivity revenue $18.59B. Reports Q1 Intelligent Cloud revenue $24.26B.

16:03 EDT Micron collaborates with Qualcomm on generative AI for smartphones - Micron (MU) announced that it is now shipping production samples of its low-power double data rate 5X, or LPDDR5X, memory the industry's only 1-beta mobile-optimized memory for use with Qualcomm's (QCOM), latest mobile platform, Snapdragon 8 Gen 3. Running at the world's fastest speed grade of 9.6 gigabits per second, Micron LPDDR5X provides the mobile ecosystem with the performance needed to unlock generative artificial intelligence at the edge.

15:48 EDT Abri SPAC I Inc trading halted, volatility trading pause

15:20 EDT Consortium says Hollysys management bid 'empty gesture already used' - A buyer consortium led by Recco Control Technology and Dazheng Group issued a statement regarding Hollysys Automation Technologies' update on its ongoing sale process and disclosure of a supposed management-backed buyout proposal, stating in part: "Dating back to August 2021, Hollysys has publicly announced multiple take private offers from its management team. Ironically, the only two times Hollysys management has expressed apparent interest in taking the company private have coincided with the time periods when the Hollysys Board was evaluating proposals from unaffiliated bidders... An important aspect of any sale process is for a Board of Directors or independent Special Committee to solicit and internalize the views of its shareholders. This sale process is no different. The Consortium believes it is the best course of action for the Hollysys Board and Special Committee to listen to the views of its shareholders. An independent Board elected by shareholders is the best way to ensure unaffiliated shareholders' interests are protected during this sale process. In its announcement today, the Board has essentially confirmed that certain shareholders owning nearly a third of shares outstanding have provided updated materials with the proper record date - a date that was set by the Hollysys Board. Now that shareholders have provided the Board with updated materials, the Consortium fully expects the Board to fulfill its fiduciary and legal obligation to convene a special meeting without delay... The Consortium reiterates its interest in acquiring Hollysys and motivation to enter due diligence and further negotiations with the Special Committee. The Consortium is confident its all-cash offer of US$25 per share is at an attractive premium and would see significant support from Hollysys shareholders. The Consortium looks forward to conducting due diligence and engaging constructively with the Special Committee."

15:05 EDT Qualcomm launches premium Snapdragon 8 Gen 3 for smartphones - At Snapdragon Summit, Qualcomm Technologies announced its latest premium mobile platform, the Snapdragon 8 Gen 3, calling it "a true titan of on-device intelligence, premium-tier performance, and power efficiency." "Snapdragon 8 Gen 3 infuses high-performance AI across the entire system to deliver premium-level performance and extraordinary experiences to consumers. This platform unlocks a new era of generative AI enabling users to generate unique content, help with productivity, and other breakthrough use cases. Each year, we set out to design leading features and technologies that will power our latest Snapdragon 8-series mobile platform and the next generation of flagship Android devices. The Snapdragon 8 Gen 3 delivers," said Chris Patrick, senior vice president and general manager of mobile handsets, Qualcomm Technologies. Reference Link

15:01 EDT Forbion European Acquisition Corp trading resumes

14:25 EDT UniFirst boosts quarterly dividends, announces new $100M buyback - UniFirst declared increased quarterly cash dividends of 33c per share on its common stock and 26.4c per share on its class B common Stock. Both dividends are payable on January 4, to shareholders of record on December 7. UniFirst also announced that its board authorized a new share repurchase program allowing the company to repurchase up to $100M of its outstanding common shares, inclusive of the amount which remained available under the existing share repurchase program approved in October 2021.

14:23 EDT Medtronic announces four-year results from Evolut Low Risk Trial - Medtronic announced four-year results from the Evolut Low Risk Trial. "The Medtronic Evolut transcatheter aortic valve replacement - TAVR - system demonstrated exceptional outcomes and sustained valve performance, proven by significantly better hemodynamics than surgical aortic valve replacement - SAVR. Only Evolut TAVR has reported consistently lower and diverging rates of death or disabling stroke versus state-of-the-art surgery, at four years. The data were presented at the 35th Transcatheter Cardiovascular Therapeutics conference, the annual scientific symposium of the Cardiovascular Research Foundation and simultaneously published in the Journal of the American College of Cardiology," the company stated.

14:07 EDT Tractor Supply introduces Yeti products to outdoor gear line-up - Tractor Supply (TSCO) announced that starting October 30, an assortment of Yeti (YETI) products will begin rolling out at select Tractor Supply stores. As consumer interest in outdoor and active lifestyles grows, Tractor Supply says it "remains committed to providing customers with a superior assortment of products that will now include a variety of YETI's popular Tundra and Roadie Hard Coolers, Hopper Soft Coolers, Rambler and Yonder drinkware, and equipment like LoadOut Buckets, LoadOut GoBoxes, and Boomer Dog Bowls, all in various sizes and colors, available at select stores." Starting October 30, Yeti will be available in Tractor Supply Project Fusion stores with an extended assortment online.

13:43 EDT Sony's Media Molecule to lay off staff - Video game developer Media Molecule, creator of games such as "Dreams" and "LittleBigPlanet," said it is laying off staff amid "significant strategic changes." "We have had to make the difficult decision to begin the consultation process for team members within certain departments of the studio," the company said. "This is a tough moment for the individuals impacted and the studio overall. Every single role that has bene put at risk id delivered by someone who has contributed something special to Media Molecule. We will make sure those impacted receive the best support we can provide during this process." Media Molecule is a subsidiary of Sony's PlayStation Studios. Reference Link

13:02 EDT Teck Resources withdraws environmental permit application for QBME project - Teck Resources noted that today, following recent receipt of feedback from regulators, it has withdrawn the environmental permit application for the Quebrada Blanca Mill Expansion, or "QBME," project to allow time to consider this feedback, better understand the full capability of QB, and submit a revised permit application. "This is part of the ongoing regulatory process, and withdrawing now will allow time to incorporate regulatory feedback and to further optimize the scope of the project. Submission of a revised application would add approximately 12 months to the overall regulatory process from the date of submission. Teck does not anticipate a sanction decision on QBME prior to completion of ramp up and assessment of the full capability of the existing QB asset and receipt of regulatory approval. The QBME project is a proposed future expansion which would increase QB's throughput, leveraging existing tailings and other infrastructure with minimal additional footprint," Teck stated.

12:39 EDT American Electric boosts quarterly dividend to 88c from 83c per share - American Electric Power declared a regular quarterly cash dividend of 88c per share on the company's common stock, an increase of 5c per share. The increase is in line with the company's 6% to 7% operating earnings growth range, it said in a statement. The dividend is payable December 8, to shareholders of record as of November 10, 2023. "We're proud to continue AEP's more than 110-year tradition of consistently delivering quarterly dividends to our shareholders," said Julie Sloat, AEP CEO. "AEP is de-risking and simplifying our business to generate the most value for customers and investors, and we remain focused on investing in our regulated operations to build the energy system of the future that supports the changing needs of our customers."

12:29 EDT NextEra takes $900M impairment for NextEra Energy Partners investment - NextEra Energy Resources (NEE) said its Q3 GAAP results include an approximately $900M after-tax impairment of its investment in NextEra Energy Partners (NEP). In 2018, NextEra Energy Resources recorded an after-tax gain of approximately $3B when NextEra Energy Partners was deconsolidated. Both the gain in 2018 and loss in 2023 have been excluded from adjusted earnings, the company said. Shares of NextEra Energy are up 7% to $54.99 following this morning's Q3 report.

12:00 EDT Calix falls -21.0% - Calix is down -21.0%, or -$8.96 to $33.62.

12:00 EDT TransUnion falls -25.6% - TransUnion is down -25.6%, or -$16.62 to $48.23.

12:00 EDT Anywhere Real Estate rises 19.9% - Anywhere Real Estate is up 19.9%, or 82c to $4.94.

11:33 EDT Tingo Group signs agreement in Pakistan for rollout of businesses - Tingo Group announced that it has executed a Memorandum of Understanding with the Khyber Pakhtunkhwa Information Technology Board to launch and roll out the company's business and service offerings into Pakistan. KPITB is a governmental body established in the Province of the Khyber Pakhtunkhwa, Pakistan, for the promotion of information technology for the public and private sector. Under the terms of the MOU, KPITB has agreed to assist Tingo by facilitating various initiatives in the Khyber Pakhtunkhwa province as well as throughout Pakistan, including the following: Implementation of Tingo's technology applications and platforms in the agricultural sector with the goal of increasing crop yields and reducing post-harvest losses; Utilization of Tingo's platforms to improve farmers' access to agricultural finance, farming knowledge, techniques and know-how, and farming inputs such as high-quality seeds and fertilizers; Promotion of sustainable farming practices and resource conservation, as well as collaboration with educational institutions to build a stronger agricultural ecosystem. The non-binding MOU establishes the framework upon which Tingo and KPITB are expected to develop a binding definitive agreement in the coming weeks consistent with these terms.

11:05 EDT Nvidia, Lenovo announce expansion of hybrid AI partnership - Lenovo (LNVGY) and Nvidia (NVDA) announced an expansion of their partnership with new, hybrid solutions and engineering collaboration that "supports their shared vision to bring the power of generative AI to every enterprise." "In close collaboration with NVIDIA, Lenovo will deliver fully integrated systems that bring AI-powered computing to everywhere data is created, from the edge to the cloud, helping businesses easily deploy tailored generative AI applications to drive innovation and transformation across any industry. The offerings were described by Lenovo Chairman and CEO Yuanqing Yang and Nvidia founder and CEO Jensen Huang at the annual global Lenovo Tech World keynote held in Austin, Texas," the companies stated. "At the center of the companies' expanded partnership are the Lenovo ThinkSystem SR675 V3 server and ThinkStation PX workstation, which are optimized for production AI running NVIDIA AI Enterprise. The ThinkSystem SR675V3 will include NVIDIA L40S GPUs, NVIDIA BlueField-3 DPUs and NVIDIA Spectrum-X networking. The ThinkStation PX will bring expanded AI capability and data center performance to the desktop by enabling up to 4x NVIDIA RTX 6000 Ada GPUs in a system. Additionally, Lenovo and NVIDIA will create next-generation systems based on the flexible NVIDIA MGX modular reference design to deliver a wide range of robust and secure solutions for the most demanding generative AI workloads and help businesses implement immersive simulations and cognitive decisions at scale with NVIDIA Omniverse, a platform for connecting and developing OpenUSD applications. The Lenovo solutions will also support the recently announced VMware Private AI Foundation with NVIDIA, enabling the hundreds of thousands of VMware customers to streamline adoption of generative AI," the companies added.

10:35 EDT Southwest Gas rises after Corvex boosts stake, plans talks - Shares of Southwest Gas are up 30c, or 0.5%, to $57.44 in morning trading after Keith Meister's hedge fund Corvex Management disclosed a 5.8%, or 4,153,717 share, stake in the company after the close. In the filing disclosing the increased stake in Southwest, Corvex stated in part: "The Reporting Persons intend to enter into discussions with the Issuer's Board of Directors and management of the Issuer to discuss options to unlock the value of the Issuer's core utility franchises and its investment in Centuri Group, Inc. The Reporting Persons are supportive of the Issuer's announced plan to separate Centuri in a manner which maximizes value. However, based on Corvex's analysis, the Reporting Persons believe the Issuer's regulated portfolio, Southwest Gas Corporation, is trading at or below its currently authorized rate base. The implied valuation represents a deep discount to underlying value, market comps, and recent transactions - where similar assets trade at 1.5 - 2.0x rate base. If the current valuation disconnect persists, the Reporting Persons believe the Issuer will be required to take further action. In the Reporting Persons' view, Southwest's ambitious $2B capital plan clearly does not make sense if growth capital results in a market valuation less than cost. The Reporting Persons anticipate engaging with the Issuer on ways to enhance shareholder value, including: improving earned returns on capital, further restructuring, and/or a sale of the Issuer."

10:00 EDT Aaron's falls -15.1% - Aaron's is down -15.1%, or -$1.34 to $7.55.

10:00 EDT TransUnion falls -21.0% - TransUnion is down -21.0%, or -$13.60 to $51.25.

10:00 EDT Amneal Pharmaceuticals rises 17.2% - Amneal Pharmaceuticals is up 17.2%, or 58c to $3.94.

09:56 EDT Archer Daniels expects 'another strong year in 2024' - Expects crush margins "to remain healthy." Seeing "incredible demand" for U.S. soybean meal. Expects Nutrition business to return to growth in 2024, but at a rate lower than previously thought. Expects "stronger pace" of buybacks in Q4.

09:47 EDT Falcon's Beyond Global Inc trading halted, volatility trading pause

09:47 EDT Aaron's falls -18.1% - Aaron's is down -18.1%, or -$1.61 to $7.28.

09:47 EDT ProShares Bitcoin Strategy ETF rises 9.9% - ProShares Bitcoin Strategy ETF is up 9.9%, or $1.58 to $17.59.

09:47 EDT Aspen Aerogels rises 12.4% - Aspen Aerogels is up 12.4%, or 83c to $7.50.

09:43 EDT Hollysys management offers $25 per share take-private deal - Hollysys Automation Technologies announced that its special committee of independent directors has received a non-binding proposal from representatives of the management team, Lei Fang and Yue Xu, the company's co-Chief Operating Officers, to acquire all of the outstanding ordinary shares of the company they do not already own for a cash consideration of $25 per share as part of a taking-private transaction. The proposal does not constitute a binding commitment with respect to the proposed transaction at this current stage, the company said in a statement. As previously announced, on October 2, Hollysys formed a special committee of the company's independent directors to conduct a formal structured sale process. In addition to reviewing the management buyout offer, the special committee and its advisors are conducting "an expedited process to solicit and review serious and compelling offers with the aim of providing bidders with the opportunity to participate on a level playing field." No decision has been made at this point with respect to the management buyout offer or other offers. The special committee "will continue its engagement with other prospective bidder groups with a focus on obtaining the best outcome for shareholders based on value and certainty. It anticipates that it will take several more weeks to establish a short-list of prospective bidders."

09:39 EDT Hollysys managements offers $25 per share take-private deal - Hollysys Automation Technologies announced that its special committee of independent directors has received a non-binding proposal from representatives of the management team, Lei Fang and Yue Xu, the company's co-Chief Operating Officers, to acquire all of the outstanding ordinary shares of the company they do not already own for a cash consideration of $25 per share as part of a taking-private transaction. The proposal does not constitute a binding commitment with respect to the proposed transaction at this current stage, the company said in a statement. As previously announced, on October 2, Hollysys formed a special committee of the company's independent directors to conduct a formal structured sale process. In addition to reviewing the management buyout offer, the special committee and its advisors are conducting "an expedited process to solicit and review serious and compelling offers with the aim of providing bidders with the opportunity to participate on a level playing field." No decision has been made at this point with respect to the management buyout offer or other offers. The special committee "will continue its engagement with other prospective bidder groups with a focus on obtaining the best outcome for shareholders based on value and certainty. It anticipates that it will take several more weeks to establish a short-list of prospective bidders."

09:33 EDT RTX to sell Cybersecurity, Intelligence, and Services business for $1.3B - RTX announced earlier that it has entered into a definitive agreement to sell its Cybersecurity, Intelligence and Services business within its Raytheon segment. The sale price is approximately $1.3B and is subject to regulatory approvals and other customary closing conditions. RTX shares are up 7.1% in early trading to $78.54.

09:22 EDT Briggs Advisory to join Focus partner firm Buckingham Strategic Wealth - Focus Financial Partners entered into a definitive agreement under which Briggs Advisory Group, a registered investment adviser based in Lincoln, RI, will join Focus partner firm Buckingham Strategic Wealth. This transaction is expected to close in the fourth quarter of 2023, subject to customary closing conditions. Briggs Advisory Group partner and wealth advisor Harold "Skip" Briggs Jr., partner and wealth advisor Christopher "Chris" Ricci and their team have used comprehensive planning and evidence-based investment management to help their clients achieve their personal financial goals. Briggs has also been an active member of Buckingham's affiliated turnkey asset management platform, Buckingham Strategic Partners, LLC, leveraging the platform's outstanding services, resources and support.

09:12 EDT Learn CW Investment Corp trading resumes

09:11 EDT Eguana, FinanzDesk to bring energy storage to European customer base - Eguana Technologies announces it has formed a multi-year, exclusive partnership with Duesseldorf based FinanzDesk, a modern financial service provider, with specialty in renewables, to bring the Eguana Enduro and future Eguana products, to its residential rooftop solar customer base of over 8,000. The Enduro, which was developed specifically for European markets, is a complete all-in-one custom-engineered energy storage platform. "We are excited to form this partnership with FinanzDesk and to bring the Enduro to their existing customer base," commented Eguana GmbH CEO Andreas Rueckemann. "The Enduro is a perfect system for both retrofit and new installation customers. With very quick installation times and a simple commissioning process, the Enduro will bring more energy security to consumers." The multi-year deal targets several thousand systems. The first order has been shipped to FinanzDesk, and program rollout has commenced.

09:09 EDT Liquidity Services's Bid4Assets selected by Armstrong County sheriff's office - Bid4Assets, a wholly owned subsidiary of Liquidity Services, has been selected by the Armstrong County, Pennsylvania Sheriff's Office to host the county's first-ever virtual sheriff's sale. The first sale will be held on October 26, 2023, with 27 properties currently listed. By moving online, the sheriff's office intends to streamline the auction process and increase accessibility by allowing all participants to bid remotely. The online format exposes the properties to a larger group of potential buyers, increasing the likelihood of third-party sales and excess proceeds for defendants, while reducing the number of properties that lenders will need to purchase.

09:07 EDT Inuvo releases version 2.0 of AI-powered Audience Discovery Portal - Inuvo announced the release of the Audience Discovery Portal 2.0, the latest version of a first-of-its-kind intelligence, capable of instantly generating marketing audience insights powered by its proprietary language model, IntentKey. The updated portal allows users to explore multiple audiences simultaneously, introduces consumer sentiment associated with an audience, shows the engagement of audiences across geographies, and captures the historical trends of each audience. Portal 2.0 provides a user-friendly interface to access AI-powered audience insights. Key features include: Instantly generated audience models based on any combination of concepts associated with that audience; Shareable reports and visualizations providing transparency into modeled audiences; Monthly, weekly, and just-in-time audience trending information. "The Audience Discovery Portal 2.0 puts the power of AI into the hands of marketers, allowing them to instantly gain understanding and insights associated with their potential customers," said Richard Howe, CEO of Inuvo. "This represents our commitment to the market shift away from legacy tracking methods. Our approach aligns with consumer and brand expectations related to privacy while outperforming traditional targeting methods."

09:06 EDT Alpha Tau announces Hahn has joined its Scientific Advisory Board - Alpha Tau Medical announced that Stephen Hahn, M.D., former commissioner of the U.S. Food and Drug Administration, FDA, has joined its Scientific Advisory Board. A distinguished expert in the field of radiation oncology and translational/clinical research, and a renowned physician, Dr. Hahn brings a wealth of regulatory and scientific experience to the Company as it advances its Alpha DaRT technology towards FDA clearance. Dr. Hahn is currently CEO-Partner of Flagship Pioneering and CEO of Harbinger Health, where he specializes in innovating in the field of preventive health care and global health strategy.

09:06 EDT Calix affirms 2024 margin expansion target of 100-200 basis points - The company said this is off of a higher margin base coming out of 2023.

09:05 EDT GeoVax Labs announces update on key strategic initiatives - GeoVax Labs announced an update on key strategic initiatives."The third quarter marked advancements in our next-generation COVID-19 vaccine clinical programs and our cancer therapy program, along with advanced manufacturing developments, and new patents issued for our Ebola, Marburg, Malaria, and HIV vaccines. I look forward to sharing more details about these developments during our upcoming investor/analyst earnings call on November 8," said David Dodd, GeoVax's Chairman and CEO. "We believe this is a defining moment for the Company, as we expand the full potential of a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials and the broad application of Gedeptin against solid tumors. We are gearing up to announce initial data readouts from two of these trials, along with updates from our Gedeptin clinical trial against advanced head and neck cancer as well as other important corporate developments. We believe that these upcoming catalysts will have a profound impact on patients in need and all our stakeholders."

09:03 EDT Cuentas launches its telecommunications, signs $4M distribution agreement - Cuentas introduces its Cuentas Mobile telecommunications services in designated markets and initiate a partnership with a well-established retail distribution network. The launch of our telecommunications services is a significant milestone in the ongoing execution of Cuentas' strategic plan and product development. Under the terms of the comprehensive agreement, its new distribution partner will initiate an initial order of 5,000 SIM cards. In addition to this, Cuentas is poised to offer cross-selling opportunities for its domestic and international mobile service top-up, gift cards, and transit cards. The company anticipates an estimated annual revenue of $4 million from this agreement. Its expansion plans will extend to new geographic markets, with a strong focus on serving Hispanic diaspora clients, providing them with a tailored and competitive product. Moreover, Cuentas will incorporate the cutting-edge digital and mobile protection software of WHEN Group, branded as "Cuentas 360."

08:57 EDT Infinite Acquisition Corp trading halted, news dissemination

08:55 EDT Cleveland-Cliffs says has reduced debt about 60% in past three years - Says shipments remain resilient, especially in automotive sector. Expects "solid performance in costs" to continue in 2024. Says UAW strikes have not materially impacted the company. Says majority of shipments don't go to Detroit three. Expects about 4M tons of shipments in Q4. Says hydrogen "is the future." Comments taken from Q3 earnings conference call.

08:52 EDT General Motors: Inventory in 50-60 range

08:49 EDT Blink Charging's Blue Corner is now Blink Charging - Blink Charging announced that its wholly-owned subsidiary, Blue Corner, is now Blink Charging, bringing the Company's global experience and EV charging expertise to Belgium. "As the EV market continues to grow throughout Europe, the acquisition and rebranding of Blue Corner was a strategic move to build a stronger and more rapid presence in the region, tapping into the strong global experience and assets while also making EV charging more accessible," said Brendan Jones, President and CEO for Blink Charging. "Blink Charging is focused on developing the market and providing the needed infrastructure to meet the demands of businesses and drivers with advanced state-of-the-art EV charging solutions." Now operating as Blink Charging, customers and clients will benefit from the vast experience of Blink Charging along with its sizable team to support the scale of the business.

08:48 EDT Intelligent Bio Solutions' drug screening technology now offered in New Zealand - Intelligent Bio Solutions announced its expansion into the New Zealand market, representing a significant milestone in the Company's growth strategy for its Intelligent Fingerprinting Drug Screening System. Harry Simeonidis, President and CEO of Intelligent Bio Solutions, said, "We are delighted to announce our expansion into New Zealand and observe another key growth milestone. Our primary focus is to meet the screening needs and support the health and safety initiatives of businesses across New Zealand and around the world. Drawing on our success in Australia over the past six months, we aim to continue this progress in New Zealand and other markets by offering an alternative and innovative solution that places a strong emphasis on operational efficiency, fitness for duty, and employee privacy and dignity."

08:47 EDT MeiraGTx announces eight presentations at ESGCT - MeiraGTx announced the Company will exhibit eight posters and deliver one oral presentation at the European Society of Gene and Cell Therapy, ESGCT, 2023 Annual Congress, which is being held from October 24-27, 2023, in Brussels, Belgium. The details of the oral and poster presentations are below: Oral Presentation OR82: Preclinical Efficacy of AAV-hUPF1 with an optimized vector genome and novel CNS capsid: Gene Therapy for ALS and FTD. At 4.9 kb, the optimized hUPF1 construct is 1.5 kb smaller than the original, thus offering AAV packaging and manufacturing benefits while demonstrating greater efficacy. When tested in vitro, the optimized AAV-hUPF1 rescued toxicity in both the TDP-43 and C9orf72 iNeurons models, at lower MOIs than the original. Optimized AAV-hUPF1 also rescued the pathophysiology of neurons derived from C9orf72 patient cell lines. Furthermore, we developed a novel AAV capsid that expresses in neurons of both the brain and spinal cord when administered by ICM in mice. Poster #008: Results of a phase 1 open-label, dose escalation study of gene therapy with AAV2-hAQP1 as treatment for radiation-induced xerostomia and parotid gland hypofunction. AAV2-hAQP1 was safe and well-tolerated at all dose levels, with no treatment-related serious adverse events or dose limiting toxicity. At Month 12, 16 of the 24 participants had an improvement of greater than or equal to8 points in XQ score, and 18 of the 24 reported important improvement in xerostomia symptoms relative to baseline on the GRCQ. In bilaterally treated participants, the average percent increase in unstimulated whole saliva flow rate at Month 12 post-treatment relative to baseline was 82.1%. Poster #116: fDISCO evaluation of AAV mediated gene expression upon different routes of administration. Detection methods to assess gene transfer mediated expression of reporter proteins in tissue requires to dissect or slice the sample, during which the three-dimensional structure is lost. On the other hand, live imaging often does not provide enough resolution to identify reporter protein expression on a cellular level. Here, we have tested whether fDISCO could overcome these limitations. In conclusion, fDISCO is able to capture the complete histological information of fluorescent reporter signal, thus being a suitable method to study the AAV-mediated reporter expression on the cellular level in 3D tissue samples. Poster #122: Development of alternatives to Triton X-100 cell lysis for AAV2, AAV5 and AAV8 primary recovery. Triton X-100 is an effective detergent for recovering biological products from intracellular compartments, but its use is now prohibited by Registration, Evaluation, Authorisation and Restriction of Chemicals regulations as its degradation generates a compound that negatively impacts aquatic life. This study demonstrates two optimized alternative AAV release methods to substitute the use of Triton X-100 that showed comparable product recovery and product quality profiles.

08:43 EDT GM: New Bolt to save billions in capital spending vs. prior plan

08:42 EDT PublicSq. launches partnership with Tucker Carlson's Last Country - PSQ Holdings announced the Company has entered into a partnership agreement with Tucker Carlson's digital media company, Last Country. The agreement includes collaborative content segments that will air on Tucker Carlson's show on both X and Last Country's own platform, focused on highlighting the patriotic, parallel economy found on PublicSq. "This content partnership between our two companies will employ a reach not found anywhere in the mainstream media today. We believe Tucker's ardent protection of American liberties strongly resonates with our target market, as evidenced by his average views totaling over 60 million per video on X. PublicSq. is thrilled to collaborate with Last Country, Inc. as we build an ecosystem of alternatives to the existing commerce and media incumbents, respectively," commented Michael Seifert, Founder, Chairman and Chief Executive Officer. Mr. Seifert continued, "This partnership is the first of its kind, and we believe it will significantly outpace our return on investment than that from traditional advertising."

08:41 EDT General Motors CEO: New Bolt to use LFP batteries

08:40 EDT Harte Hanks appoints Kelly Waller as SVP, sales and marketing - Harte Hanks announced that Kelly Waller has agreed to join Harte Hanks as Senior Vice President of Sales and Marketing. Ms. Waller is relocating to Boston, working in close proximity to Kirk Davis, Chief Executive Officer, as part of the Harte Hanks senior leadership team. For the past seven years, Ms. Waller has served as Global Vice President, Mid-Market for Finastra.

08:38 EDT GM launching new SUVs with profit margins 5 points higher than previous models - Comments taken from Q3 earnings conference call.

08:37 EDT Cellebrite announces highlights of 2023 IACP Conference - Cellebrite (NASDAQ: CLBT), a global leader in Digital Intelligence ("DI") solutions for the public and private sectors, wrapped up a four-day presence at the 2023 International Association of Chiefs of Police (IACP) Annual Conference and Exposition. More than 16,000 police chiefs and other senior law enforcement professionals attended the single largest and most impactful law enforcement event of the year. Highlights of Cellebrite's event presence include: Center-floor exhibition booth space with demonstrations and presentations of the full suite of Cellebrite end-to-end solutions for the public sector including Pathfinder and Guardian; Cellebrite's CEO and President of North America convened with DEA senior leadership, 132 senior law enforcement and chief leaders to discuss streamlining and modernizing the handling of digital data from time of extraction to prosecution; Multiple meetings with key officials representing many of the largest cities across America with 60 product demonstrations and more than 500 times as many booth visits when compared to 2022; An interactive "Solve Suite" where law enforcement gained hands-on experience using Cellebrite's powerful digital intelligence solutions, including demoing its newest innovation, Smart Search, which led a police chief to expedite a request for Cellebrite solutions that was sitting on his desk; Panel moderation by Jared Barnhart, Digital Intelligence Specialist at Cellebrite, with key partners in the fight against human trafficking, including the National Center for Missing and Exploited Children, the Exodus Road and Raven - this powerful panel was one of the top-attended programs at the event; Presentation of "Unraveling Crime Mysteries" with Jared Barnhart, Digital Intelligence Specialist at Cellebrite, who shared his law enforcement expertise while discussing real-world examples of how digital intelligence solutions can enhance investigations to solve cases faster, smarter and more defensibly to accelerate justice; Connect Lounge Sponsorship, a popular meeting spot for law enforcement professionals to network with one another The panel discussion on child trafficking was a remarkable convergence of global leaders committed to safeguarding children worldwide. They united to synergize their collective expertise for an accelerated mission. It called upon all law enforcement agencies and technology vendors to integrate cutting-edge solutions and increase the number of rescued children. The "Unraveling Crime Mysteries" presentation illuminated cases solved through technology, emphasizing the need for agencies to adopt smarter, tech-driven approaches. In its entirety, these platforms at IACP emphasized Cellebrite's unwavering commitment to collaborate with philanthropic and agency partners, aiming to make the modernization of investigations a reality, simplifying and expediting critical cases.

08:35 EDT Repay Holdings partners with Kredit to streamline payment collections - Repay Holdings Corporation announced a new partnership and technology integration with Kredit Financial or Kredit , a leading digital debt resolution platform and network. The collaboration enables collection agencies, debt buyers and collection law firms that use Kredit's technology platform to offer flexible payment methods that reduce friction and increase transparency and accountability in every financial transaction. Through the integration, Kredit users will be able to accept card and ACH payments directly through Kredit's debt resolution platform, streamlining the payment collection process and enabling businesses to optimize internal workflows and simplify reconciliation. Providing easily accessible and secure ways to pay, including through Kredit's online portal, improves collection efforts by empowering consumers to pay when it's most convenient for them.

08:35 EDT AbbVie's Allergan Aesthetics reports positive Phase 3 results in glabellar lines - AbbVie company Allergan Aesthetics announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE - BoNT/E - for the treatment of moderate to severe glabellar lines. The Phase 3 studies evaluated the safety and efficacy of BoNT/E versus placebo in a total of 947 adult subjects with moderate to severe glabellar lines located between the eyebrows in the U.S., Canada, and Europe. The primary endpoints of both pivotal Phase 3 studies demonstrated statistical significance for improvement with BoNT/E versus placebo in glabellar line severity on the Facial Wrinkle Scale from baseline at day 7. All tested secondary endpoints, including patient-reported outcomes on overall treatment satisfaction, demonstrated statistical significance, favoring improvement with BoNT/E versus placebo. The onset of efficacy was demonstrated at 8 hours after drug administration and efficacy duration was observed for 2-3 weeks after drug administration. Treatment-emergent adverse events for BoNT/E were similar to placebo, both as a single treatment and up to two consecutive treatments. Additional study results will be submitted for presentation at future medical meetings. A Phase 3 open-label safety study is ongoing, with results expected later this year.

08:31 EDT CAE sells healthcare business for C$311M - CAE has reached a definitive agreement to sell CAE's Healthcare business to Chicago-based Madison Industries for an enterprise value of C$311M, subject to customary adjustments. Closing of the transaction, which is subject to closing conditions, including customary regulatory approvals, is expected before the end of FY24. Sale proceeds will be principally used to accelerate deleveraging, as well as to support CAE's continued focus on technology advancement, market leadership and cost optimization within its core training and simulation markets.

08:30 EDT Quoin announces additional clinical data from trial in Netherton Syndrome - Quoin Pharmaceuticals announces additional positive clinical data from its ongoing open-label study evaluating the safety and efficacy of QRX003 as a potential treatment for Netherton Syndrome. This study, which is being conducted under Quoin's open Investigational New Drug application, is an open-label, single-arm trial that is evaluating 10 NS patients dosed with QRX003 over a twelve week period. All subjects in the study are continuing to receive off-label systemic therapy for the duration of the trial. Of the available data from six evaluable subjects, five demonstrated a well-defined positive improvement in pruritus, or itch, with those five subjects reporting absent or negligible pruritus on completion of dosing with QRX003 based on the endpoint scoring system. The sixth subject's pruritus was effectively unchanged on completion of dosing with QRX003. In the Investigator assessed skin scoring system, all six patients experienced an improvement in skin appearance, with three of the six subjects demonstrating improvement throughout the study, while for the other three subjects, signs of improvement were exhibited at various points throughout the dosing period. Importantly, all of the 6 subjects indicated a positive impression of QRX003 across a number of key metrics. Quoin CEO, Dr. Michael Myers, said, "While acknowledging that this is still early stage data, we are very pleased to announce today additional positive results from our ongoing open-label study in Netherton Syndrome. In August of this year, we announced positive data from the first subject, who completed the 12-week dosing period in the study, and I'm now delighted to provide a further positive update for an additional five subjects. The results for pruritus are particularly encouraging, as this often causes significant distress for Netherton patients. In addition, there are well defined efficacy signals across the other evaluated endpoints including skin appearance and the subjects' own impression of how QRX003 performed throughout the study, indicating that QRX003 may have the potential to become an effective treatment for Netherton Syndrome. Furthermore, the absence of any safety concerns from the study to date is a positive indicator for the ongoing clinical development of the product."

08:28 EDT Microbot receives confirmation for commencement of CE Mark approval process - Microbot Medical announces it has received confirmation for the commencement of the process to support its future CE Mark approval, and to ultimately allow the Company to market the LIBERTY Robotic Surgical System in Europe as well as other regions who accept the CE Mark. According to the confirmation, the Company will commence audits for ISO 13485 certification to ensure its compliance with the Quality Management System requirements of the EU Medical Devices Regulation, during the first half of 2024. The Company had previously taken the first step to advance its European program by engaging with a leading Notified Body, who recently confirmed dates for conducting the required audits. "We are confident that we have taken the right measures to successfully complete these audits, which will serve as the first step in our commercial approval process for Europe as well as other regions across the globe which allow commercialization under the CE Mark," said Noa Ofer, Sr. Director QA/RA. "We intend that this process will be conducted in parallel with our FDA approval efforts, to allow us to capture as many markets across the globe as we prepare for future commercialization."

08:27 EDT Ocean Power secures $1.6M order from multiple WAM-V 16s - Ocean Power Technologies has received an additional volume order from Sulmara, a prominent player in offshore services, of WAM-V 16 uncrewed surface vehicles making this the largest single order of WAM-Vs to date. The order, valued at $1.6 million, underscores OPT's commitment to providing innovative and sustainable solutions for the offshore industry. Due to demand, production is already underway to support and will allow for revenue recognition this fiscal year.

08:25 EDT Aslan Pharmaceuticals to co-host KOL on atopic dermatitis treatment - ASLAN Pharmaceuticals will co-host a virtual investor event with a leading Clinical Research Organization, entitled "The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has Changed in the Seven Years Following Dupilumab's Introduction", at 11:00am - 12:00pm ET. Registration for the webcast is accessible online here. The webcast will include presentations by ASLAN and the CRO followed by a panel discussion with Key Opinion Leaders, Jonathan Silverberg, MD PhD MPH and April W. Armstrong, MD MPH, on the changes in the clinical trial and treatment landscape in atopic dermatitis, the impact these changes have on clinical data and new therapies, and potential solutions for optimizing AD trials. During the event, ASLAN will present additional analyses of the TREK-AD patient population building on data recently published at the 32nd European Academy of Dermatology and Venereology Congress. Eblasakimab's efficacy was shown to be comparable in all levels of disease severity studied, however, less severe disease was shown to result in a materially increased placebo response in TREK-AD and other recent studies, making placebo-adjusted efficacy critically dependent upon disease severity in the trial patient population. ASLAN will also present new insights on the AD treatment landscape based on a recently conducted survey of physicians and AD patients in the US. Among the findings, the physicians surveyed selected eblasakimab's product profile to be their biologic of choice, if available, to prescribe for AD in the first- and second-line settings after dupilumab. In addition, seventy percent of the physicians surveyed consider monthly dosing from the start of treatment to be one of the most important attributes of a new AD therapy, consistent with eblasakimab's potential dosing regimen. The patients surveyed reiterated the importance of new treatment options for AD, with over half of dupilumab patients expressing a willingness to switch to a biologic with eblasakimab's target product profile. Based on these learnings from TREK-AD, ASLAN plans to implement changes to the ongoing phase 2b TREK-DX study of eblasakimab in dupilumab-experienced, moderate-to-severe AD patients. In addition to recruiting patients in the US, ASLAN will open new sites in Europe, introduce independent reviewer confirmation of the severity of the disease, and tighten the inclusion criteria to enroll patients with a baseline Eczema Area and Severity Index score of at least 18. ASLAN will provide updated guidance on the timing for the topline readout from the study after these changes have been implemented, and confirms these changes have no impact on the Company's ongoing preparations for a phase 3 study of eblasakimab in moderate-to-severe AD.

08:23 EDT WillScot Mobile Mini adds Clearspan structures to its portfolio - WillScot Mobile Mini announced it has acquired 616 Global Clearspans, a leading national temporary and semi-permanent clearspan structure company based in Tucson, Arizona. The acquisition further extends WillScot Mobile Mini's comprehensive offering of temporary space solutions, adding capability to create more expansive space solutions for the Company's core markets and providing growth opportunities in new end markets. Tim Boswell, President and Chief Financial Officer, commented, "Adding flexible clearspan structures to our already expansive portfolio of space solutions is another step in our strategy to make it easy for companies to get the right turnkey space they need for their projects. These highly configurable and durable temporary fabric structures are commonly utilized by existing customers across virtually all end markets that we serve. They also are complementary to our existing offering and often deployed together with our other modular space and storage solutions. As with our other solutions, we see opportunities to drive value-based pricing, expand our Essentials line of Value-Added Products and Services, and bring scale efficiencies to the 616GC operations across our North American footprint, all while delivering differentiated solutions and unrivaled service levels to our customers. The 616GC team and products are a terrific addition to WillScot Mobile Mini, and we are excited about the obvious commercial synergies in the combination."

08:22 EDT Onconova appoints Moyo as CMO, Arora as VP, Global Medical Affairs, R&D - Onconova Therapeutics announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer, CMO, and the addition of Meena Arora as Vice President, VP, Global Medical Affairs and Research and Development, R&D. Dr. Moyo joined Onconova as Consulting Chief Medical Officer in August, 2023. Most recently, Arora served as Vice President/Head of Global Medical Affairs - Epidermolysis Bullosa for Amryt Pharma.

08:21 EDT Synchrony sees FY23 loan receivables growth of 11% - Sees FY23 net interest margin 15.15%. Sees FY23 net charge-offs 4.85%. Sees FY23 RSA/Average loan receivables 3.95%. Sees FY23 operating expenses $1.15B. Guidance taken from Q3 presentation slides.

08:20 EDT Transcode announce preliminary results in patient in Phase 0 study of TTX-MC138 - TransCode Therapeutics announced preliminary results with its lead therapeutic candidate, TTX-MC138, in the first patient enrolled in its Phase 0 clinical trial aimed at demonstrating delivery of TTX-MC138 to metastatic cancer, including metastases beyond those found in the liver. These preliminary data showed that radioactivity consistent with accumulation of TTX-MC138 was detected by noninvasive imaging in the regions of the metastatic lesions previously identified by fluorodeoxyglucose/positron emission tomography. In addition, radiolabeled TTX-MC138 had pharmacokinetic behavior consistent with that expected based on non-clinical IND-enabling studies. The patient tolerated the dosing with no reported adverse reactions. Metabolite analysis indicated circulation of intact radiolabeled TTX-MC138 for more than 20 hours, equivalent to that predicted by Drug Metabolism and Pharmacokinetics modelling, and that the drug candidate analyzed in the blood was identical to that of the manufactured drug candidate, demonstrating in vivo stability. The Phase 0 trial is an open-label, single-center, microdose study intended to demonstrate delivery of the radiolabeled version of TTX-MC138 to radiographically-confirmed metastases in subjects with advanced solid tumors. The trial is not intended to demonstrate a therapeutic effect. "Our Phase 0 trial involves a single microdose of radiolabeled TTX-MC138 followed by noninvasive PET-MRI imaging and metabolite analysis. Given the similarities between humans and non-human primates relative to anatomy, physiology, and molecular biology, we anticipated results in trial patients comparable to those observed in the DMPK model based on our NHP studies, as evidenced by the preliminary data we announced today," added Michael Dudley, Chief Executive Officer of TransCode.

08:17 EDT Butterfly Network announces $20M milestone in 5-yr pact with Forest Neurotech - Butterfly Network and Forest Neurotech, a deep tech research company that is building a minimally-invasive device for imaging and stimulating the brain with ultrasound, today announced they have entered into a five-year co-development agreement. The agreement includes $20MM to be paid to Butterfly for annual licensing, chip purchases, services and milestone payments, of which $3.5MM was received on signing. Additional revenue is anticipated for every unit sold upon commercialization. Forest Neurotech is the latest Focused Research Organization to be created as part of Convergent Research, an incubator for ambitious scientific non-profits and member of the Schmidt Futures Network. Convergent Research recently announced $50M in new philanthropic support...The news follows Butterfly's announcement in August 2023, launching Butterfly Garden to facilitate partnerships with medical device companies, AI companies, or software developers seeking to build new applications with its industry leading imaging platform. Butterfly's Ultrasound-on-Chip technology can operate at a wide range of frequencies, has enormous programming flexibility, and is compact in size, making it highly suitable for a variety of ultrasonic sensing use cases, including potential implantables. Since launching Butterfly Garden, Butterfly has seen a strong response to the program and the company expects additional collaboration announcements to follow.

08:17 EDT Taysha Gene Therapies presents preclinical in-vitro data on TSHA-102 - Taysha Gene Therapies announced new preclinical in vitro data on TSHA-102 in Rett syndrome as part of a poster presentation at the European Society of Gene & Cell Therapy 30th Annual Congress. TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy that utilizes a novel miRNA-Responsive Auto-Regulatory Element technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. These data demonstrate the function of the miRARE-RHD1pA regulatory element and its impact on MECP2 transgene and protein expression in human and mouse cell lines, providing further support for the regulatory control of miRARE. The preclinical study presented at ESGCT used human and mouse cell culture models to explore the function of miRARE and its impact on MECP2 transgene and protein expression in the presence or absence of cellular MeCP2 using both viral AAV9 transduction and plasmid transfection containing either miRARE-regulated or SV40 elements. In vitro data showed post-transcriptional gene silencing by miRARE in response to cellular MeCP2 levels can be recapitulated in human and mouse cell lines: miRARE controlled dose-dependent transgene expression of MeCP2 protein via a similar mechanism in both human and mouse cell lines miRARE partially silenced transgene expression in neuronal and non-neuronal cell lines; the expression and subsequent downregulation were 4-5-fold higher in neuronal cell lines, supporting tissue-specific expression of MeCP2 Transgene protein expression was highest in homozygous cells and slightly greater than wild-type in heterozygous cells, demonstrating transgene expression of MeCP2 protein is sensitive to cellular levels of MeCP2 and increases in human cells with both endogenous MECP2 copies disrupted Transgene silencing occurred in part by inducing mRNA decay but more substantially by reducing miniMeCP2 protein accumulation, suggesting that the miRARE technology also acts in cis to prevent translation

08:15 EDT DevvStream completes preparation of financial statements for combination - DevvStream Holdings provides a progress update since the execution of its business combination agreement for a business combination with Focus Impact Acquisition Corp., which is expected to result in the securities of DevvStream being listed for trade on the Nasdaq Stock Market. The Transaction values DevvStream at an implied enterprise value of approximately $212.8 million, representing an equity value of C$2.16 per DevvStream subordinate voting share prior to closing. Since executing the Business Combination Agreement, DevvStream has completed its preparation of required financial statements, prepared in accordance with U.S. GAAP and audited in compliance with Public Company Accounting Oversight Board requirements, for inclusion in the Registration Statement on Form S-4 to be filed by Focus Impact with the Securities and Exchange Commission in the coming weeks registering the securities being issued in connection with the Business Combination, which Registration Statement will also contain a proxy statement for the purpose of soliciting votes from the Focus Impact shareholders to approve the Business Combination. The Business Combination is expected to be completed by early Q1 2024, subject to the satisfaction of closing conditions under the Business Combination Agreement.

08:14 EDT electroCore announces data from abstract on nVNS - electroCore announced top line data from an abstract being presented as an oral podium presentation at the 2023 American College of Gastroenterology Annual Meeting held in Vancouver, Canada from October 23-25, 2023 regarding the potential for Non-invasive Vagus Nerve Stimulation, nVNS, to decrease the use of acute rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia. This pilot study included patients greater than or equal to15 years of age with ongoing GP or FD symptoms for a period of greater than or equal to3 months. The primary endpoint was reducing the use of antinausea medications by using nVNS as the primary rescue treatment for nausea exacerbations. Exploratory endpoints included changes in GI, autonomic, and psychological symptoms via standardized questionnaires. The study showed nVNS reduced the use of rescue pills per day by more than 50%. This benefit was maintained throughout each 4-week treatment period of the crossover study as well as during the two, two-week, washout periods. Exploratory endpoints revealed robust improvements in abdominal pain, reflux, indigestion, and constipation. Depression levels, as measured by the Beck Index, improved, and Migraine scores improved with the subjects using fewer headache/migraine pills per day during the study. No serious device-related adverse effects were reported. Peter Staats, MD, Chief Medical Officer for electroCore, commented, "We congratulate all the investigators and patients that supported this research into the role of nVNS as a novel, non-pharmacologic treatment for patients suffering from gastroparesis. The significant decrease in the use of rescue medications, combined with the many benefits seen in the accompanying symptoms that often plague patients with gastroparesis suggest a new and important role for nVNS."

08:12 EDT Motus receives FDA clearance to commercialize Pure-Vu EVS Gastro, Gen 4 Colon - Motus GI Holdings announced that it has received clearance from the U.S. Food and Drug Administration, FDA, for the special 510(k) for technological advancements featured in the new Pure-Vu EVS Gastro and Gen 4 Colon system. The Pure-Vu EVS Gastro opens the critically important upper gastrointestinal portion of the market and access to the high acuity patients that suffer from an upper GI bleed where visualization to address this high mortality condition can be a significant issue. "We are excited to receive FDA clearance for our next generation system, which features key enhancements such as a larger and more powerful suction channel, more efficient irrigation jets, and a smaller profile distal tip that offers enhanced flexibility during insertion and enhanced navigation. In addition to offering new capabilities, this latest version of our platform reduces the cost-of-goods by approximately 50% and the training requirements for the customer from hours to minutes. Based on physician feedback, we expect the Upper GI indication and these enhancements to be well received by the GI community and we believe will drive greater market adoption of the Pure-Vu EVS platform," commented Mark Pomeranz, Chief Executive Officer. "We look forward to initiating market introduction of the Pure-Vu EVS Gastro and Gen 4 Colon in the U.S. by the end of the year. Currently, we are planning to ramp up manufacturing supply and expect to have supply of both new products to customers in the coming months."

08:10 EDT Iterum announces completion of enrollment in it REASSURE Phase 3 trial - Iterum Therapeutics announced the completion of patient enrollment in its REASSURE clinical trial comparing oral sulopenem to oral Augmentin in adult women with uncomplicated urinary tract infections, uUTI. "We are extremely pleased to have completed enrollment in our REASSURE trial well ahead of schedule. We now expect topline results early in the first quarter of 2024, and subject to our analysis of the data, plan to resubmit our NDA to the FDA in the second quarter of 2024," said Corey Fishman, Chief Executive Officer. "This significant milestone represents another exciting step forward in the development of oral sulopenem and potentially bringing to market the first antibiotic approved for the treatment of uUTIs in over 25 years, as well as the first oral penem, in the U.S." Iterum expects to report topline data early in the first quarter of 2024 and, subject to its analysis of the data, to resubmit its New Drug Application for oral sulopenem for the treatment of uUTIs to the U.S. Food and Drug Administration in the second quarter of 2024.

08:09 EDT Spectral AI appoints Paul Chadwick as senior executive for UK, EMEA - Spectral AI announced the appointment of Prof. Paul Chadwick as Executive Vice President of the Company's United Kingdom subsidiary. Prof. Chadwick is an experienced clinical scientist and wound care key opinion leader with an impressive body of work including a substantial and impactful publication record, particularly in the domain of diabetic wound management. He will be responsible for the international market expansion of the Company's DeepView wound imaging technology in the United Kingdom, Europe, Middle East and Africa, all of which are geographic areas where Prof. Chadwick has extensive clinical networks, significant experience and has enjoyed previous successes. In his previous roles at the Royal College of Podiatry, Prof. Chadwick led all the clinical, educational and financial aspects of the organization.

08:08 EDT Latham Group appoints Gloe as CFO - Latham Group (SWIM) announced the appointment of Oliver Gloe as Chief Financial Officer, CFO, effective November 13, 2023. Gloe will join Latham on October 30, 2023 as Vice President, Finance before assuming the role of CFO. As CFO, Gloe will oversee Latham's finance, strategic planning, investor relations, treasury, tax and accounting reporting functions and report to Latham President and Chief Executive Officer, Scott Rajeski. Mark Borseth, who currently serves as Interim Chief Financial Officer, will transition to the role of Strategic Advisor to the Company beginning November 13, 2023 through December 31, 2023. Gloe brings over 20 years of experience leading finance teams within global manufacturing companies. He joins Latham after serving with Fortune Brands Innovations (FBIN) as the Chief Financial Officer, Outdoors & Security.

08:08 EDT Pulse Biosciences appoints Niv Ad, M.D. as Chief Science Officer - Pulse Biosciences announced the appointment of Niv Ad, M.D. as Chief Science Officer, Cardiac Surgery. "After working with the Pulse Biosciences' team and participating in preclinical studies using the nsPFA clamp for cardiac ablation, it was immediately clear to me that nsPFA has the potential to not only replace all other energy modalities in cardiac ablation, including radiofrequency and cryo, but due to the speed, safety, and ablation performance of the system, it has the potential to significantly expand the number of patients we treat in cardiac surgery," said Dr. Niv Ad, Chief Science Officer, Cardiac Surgery. "Because of this and how far along the Company is in the development of a commercially viable system, I decided to join this experienced team as it enters this next exciting phase of bringing nsPFA from the lab to the clinic to make a positive impact on patient lives and healthcare. I look forward to working alongside this impressive team."

08:06 EDT Connexa Sports Technologies enters distribution agreement for Padel Tennis - Connexa Sports Technologies has agreed a multi-year distribution agreement covering all global markets for Padel Tennis with Desarrollo y Promocion de Padel S.L., a division of Manza Sport based in Valencia, Spain - a company that has over 20 years of experience in the global Padel Tennis market as a leading supplier of Padel Tennis courts. From 2024, this agreement will guarantee a minimum of $4M to Connexa in annual revenue.

08:06 EDT Bragg Gaming expands iGaming content reach in Italy with Lottomatica - Bragg Gaming Group announced the expansion of its content distribution network in Italy with Lottomatica Group, "the leading online casino operator in Europe's second largest regulated online casino market. The new content distribution agreement will bring Bragg's Italian casino content portfolio, including localized versions of proprietary games such as Fairy Dust by Atomic Slot Lab and Sea of Plenty by Indigo Magic, as well as multiple locally-certified titles from the company's exclusive Powered by Bragg casino games collection, to a large new Italian audience for the first time. Lottomatica is Italy's leading online casino operator with a reported 21% market share. H2 Gambling Capital estimates online casino revenues in Italy will grow 15% this year compared to 2022 to $2.7B .

08:06 EDT IBM, KPMG expand partnership - IBM (IBM) and KPMG LLP announced they are expanding their alliance to help enable business transformations for clients implementing SAP (SAP) S/4HANA across the energy and utilities industry. Cloud enterprise resource planning projects run the potential risk of failing without the right technology in place and the right business expertise to fully integrate it. IBM Consulting and KPMG together are bringing a breadth of consulting, operations, tax, risk and finance experience to the ERP implementation process to help energy and utilities companies automate and manage core business processes for optimal performance.

07:54 EDT General Electric 'really pleased' overall with renewables

07:52 EDT Aurora Cannabis settles patent litigation with Willow Biosciences - Aurora Cannabis and Willow Biosciences have completed a confidential settlement resolving the ongoing patent litigation between the two parties in Canada. Aurora commenced a patent infringement action in July 2021, alleging that Willow's biosynthetic process for synthesizing cannabinoids infringed Aurora's exclusive rights to patents co-owned by the University of Saskatchewan and the National Research Council.

07:46 EDT Nitches, Inc. announces meeting with hospitality group - The company said, "Nitches is thrilled to share an exciting update as they gear up for the International Ft. Lauderdale Boat Show. As the company continues to build momentum and expand its horizons, Nitches recently had a pivotal meeting with a prominent and sizeable hospitality group. This meeting marks the beginning of a promising partnership aimed at investing in and expanding the renowned Tover Spirits Brand.This strategic collaboration is a significant step for Nitches as they look to forge strong relationships and partnerships in the coming year and beyond. The collective effort and expertise of both Nitches and the hospitality group are set to make a resounding impact on the luxury spirits market in 2024 and beyond. Nitches invites you to stay tuned for live tweeting of exclusive events and captivating images from the International Ft. Lauderdale Boat Show, which promises to be a highlight of the week."

07:43 EDT NeoGenomics announces commercial availability of two new tests - NeoGenomics announced the commercial availability of two new tests, expanding its cancer portfolio of innovative products. These include Neo Comprehensive- Heme Cancers, a next-generation sequencing panel with a comprehensive genomic profile of hematologic malignancies, and Early-stage Non-Small Cell Lung Cancer Panel, a therapy selection panel designed specifically for early-stage NSCLC patients.

07:41 EDT Laser Photonics commences pre-orders for CleanTech Robotic Cell Enclosure - Laser Photonics announced that pre-orders are open for its recently launched CleanTech Robotic Cell Enclosure, a programable and AI-capable product that eliminates safety concerns for human operators. This new offering is currently available to customers for pre-order, with initial deliveries anticipated in early 2024.

07:39 EDT Travelzoo announces 1M share repurchase program - Travelzoo announced that its board of directors has authorized the repurchase of up to 1M shares of the company's outstanding common stock.

07:39 EDT Citius executes definitive agreement to merge subsidiary with TenX Keane - Citius Pharmaceuticals (CTXR) and TenX Keane Acquisition (TENKU)announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma's wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange. The newly combined public company will be named Citius Oncology. Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024. Pursuant to the proposed agreement, TenX will acquire Citius Pharma's wholly owned subsidiary via a merger, with the newly combined publicly traded company to be named Citius Oncology, Inc. In the transaction, all shares of Citius Pharma's wholly owned subsidiary would be converted into the right to receive common stock of Citius Oncology. As a result, upon closing, Citius Pharma would receive 67.5 million shares of common stock of Citius Oncology which, at an implied value of $10.00 per share, would be $675 million in equity of Citius Oncology, before fees and expenses. As part of the transaction, Citius Pharma will contribute $10 million in cash to Citius Oncology. An additional 12.75 million existing options will be assumed by Citius Oncology. At closing, any cash remaining in TenX's trust account along with the cash provided by Citius Pharma will be contributed to Citius Oncology to support ongoing operations and planned commercialization efforts. Upon closing, Citius Oncology will operate under a shared services agreement with Citius Pharma, with fees payable quarterly to Citius Pharma, for the services of several key members of the Citius Pharma team, led by Leonard Mazur, Chief Executive Officer, Jaime Bartushak, Chief Financial Officer and Dr. Myron Czuczman, Chief Medical Officer. Myron Holubiak will serve as Executive Vice Chairman of the Citius Oncology Board of Directors. The proposed business combination is expected to be completed in the first half of 2024.

07:38 EDT Hyzon Motors appoints Stephen Weiland as CFO - Hyzon Motors appointed Stephen Weiland as CFO of the company, effective November 1. Weiland most recently served as CFO for Boom Supersonic where he was responsible for the supersonic aircraft manufacturer's financial and information technology functions. Prior to his role at Boom, Weiland worked at Caterpillar as a Division CFO for manufacturing and engineering, digital, and procurement divisions. Jiajia Wu, the company's interim CFO since April 2023, will transition to the role of Senior VP, Finance and Accounting.

07:37 EDT Mind Medicine completes enrollment in Phase 2a study to treat adults with ADHD - Mind Medicine announced that it has completed enrollment of Study MMED007, the Company's Phase 2a study evaluating repeated low-dose administration of MM-120 or lysergide D-tartrate, for the treatment of adults with ADHD. "We are pleased to announce the completion of enrollment of our Phase 2a study in adults with ADHD," said Robert Barrow, Chief Executive Officer and Director of MindMed. "This proof-of-concept trial is designed to evaluate the clinical effects of a sub-perceptual dose of MM-120 administered in a repeated fashion. The study's results will inform our ongoing work to establish new clinical paradigms for this promising drug candidate. We anticipate sharing topline data by the end of the first quarter of 2024." MMED007 is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MM-120 compared with a placebo administered orally twice weekly for 6 weeks in adults between the ages of 18 and 65 with ADHD. The primary endpoint in this study is mean change from Baseline in ADHD symptoms, as assessed by the Adult ADHD Investigator Symptom Rating Scale AISRS after 6 weeks of treatment. Key secondary objectives, measured up to 10 weeks after the initial dose, include assessments of ADHD symptom severity, as well as safety and tolerability.

07:36 EDT NextEra Energy Partners still sees 5%-8% growth per year in distributions

07:36 EDT PyroGenesis announces $360,000 initial contract for PACWAD system - PyroGenesis Canada announced the receipt of an initial contract valued at 250,000 EUR from a European engineering services firm undertaking the discovery and safe destruction of chemical warfare agents with the European Union. The contract includes a 45% upfront payment of the total contract value, or 112,500 EUR , which has already been received. Under this agreement, as part of a potential three-phase project PyroGenesis will first provide a lab-scale size plasma arc chemical warfare agent destruction system as part of a multi-partner project aimed at identifying, extracting, and disposing of chemical munitions and chemical warfare agents residing in active marine passageways and corridors. The second phase will consist of testing the system to validate its efficiency, performance and capacity. The eventual goal is to develop a full-scale system once results from the lab-scale system are reviewed.

07:34 EDT SAB Biotherapeutics appoints King Jr. as Chief Financial Officer - SAB Biotherapeutics announced that Michael King Jr. has been named Chief Financial Officer. King, who starts his new role on Oct. 30, replaces Russell Beyer, who is expected to step down on Nov. 15 and remain a senior advisor with the company through the end of the year. King's record of achievement includes successful engagements with Hambrecht & Quist, Alex Brown & Sons, Robertson Stephens, Vector Securities, and more

07:33 EDT Else Nutrition's Kids Shakes to list in Canadian grocery store chain - ELSE NUTRITION announces that its Ready-To-Drink Kids' Nutritional Shakes will be the first of its kind to hit the shelves of over 100 stores in November this year, in one of Canada's grocery chain stores in Ontario. This listing, in addition to all other Else products already listed with the chain, marks a significant stride in Else's Canadian market penetration strategy, providing a groundbreaking, tasteful, whole food based and lower sugar alternative in the kids' nutrition category.

07:33 EDT Prime Medicine presents first in vivo proof-of-concept prime editing data - Prime Medicine reported new preclinical data demonstrating the ability of Prime Editors to efficiently and precisely correct the predominant mutations that cause rhodopsin associated autosomal dominant retinitis pigmentosa. The data were presented today at the International Symposium on Retinal Degeneration 2023 Congress in Costa del Sol, Spain. "The data presented today are the first proof-of-concept data for Prime Editing's application in treating ophthalmological indications, and highlight the ability of Prime's novel, dual AAV delivery platform to efficiently deliver Prime Editors to the eye," said Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer of Prime Medicine. "Specifically, today's data highlight the ability of two Prime Editors to correct the predominant mutations causing RHO adRP - one to correct p.P23H, the most common disease-causing mutation in RHO in the U.S., and one to correct 18 different mutations at a mutational hotspot in RHO, including p.V345L and p.P347L, which are the most prevalent mutations in Europe. With no detected off-target edits in human photoreceptors and no AAV integrations observed in these studies, today's results are a positive step forward for those living with RHO adRP, for whom there are currently no approved treatment options." To address the predominant mutations causing RHO adRP, Prime Medicine conducted comprehensive high-throughput screening of more than 1,000 Prime Editor guide RNAs. Two potent Prime Editors were identified - one that precisely corrected RHO p.P23H located near the N-terminus of rhodopsin, and one that precisely corrected the mutational hotspot located near the C-terminus, which includes 18 pathogenic mutations including RHO p.V345L and p.P347L. In today's presentation at RD2023, Prime Medicine shared findings from in vivo studies in humanized mice with its Prime Editors targeting these prevalent RHO mutations. Key findings from these studies showed: Up to 70% precise correction in photoreceptors at RHO p.P23H and up to 65% at RHO p.V345L or p.P347L at a mutational hotspot using Prime Editors delivered by a dual AAV system via subretinal injection with less than 0.5% on-target unintended edits detected. Efficient delivery of Prime Editors by dual AAV to human and murine photoreceptors. RHO correction well tolerated with no detectable changes in retinal thickness or glial fibrillary acidic protein gene expression. No measurable integration of the AAV vector at the edit site, as measured by one-sided polymerase chain reaction. No detectable off-target edits observed in human photoreceptors following a genome-wide off-target screening analysis.

07:31 EDT General Motors 'on track' for net $2B fixed cost reduction program by 2024

07:31 EDT General Motors targeting low to mid single digit EBIT EV margin in 2024 - GM says it expects to have annual EV capacity of 1 million units in North America exiting 2025.

07:30 EDT Moderna announces first participant dosed in Phase 3 flu/COVID combo vax study - Moderna announced that the first participant has been dosed in a Phase 3 study of the company's combination vaccine candidate against influenza and COVID-19 in the U.S. The trial is expected to enroll approximately 8,000 adults in the Northern Hemisphere. The Phase 3 study will evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and SAR-CoV-2 vaccines in two independent age-group sub-study cohorts involving 4,000 adults 65 years and older and 4,000 adults 50 to less than 65 years of age. "The mRNA-1083 candidate selected to advance to Phase 3 achieved hemagglutination inhibition antibody titers similar to or greater than both licensed quadrivalent influenza vaccines and achieved SARS-CoV-2 neutralizing antibody titers similar to the Spikevax bivalent booster in the Phase 1/2 study. mRNA-1083 has the potential to efficiently reduce the overall burden of acute viral respiratory diseases by providing simultaneous protection against influenza and SARS-CoV-2 viruses in a single injection. mRNA-1083 offers greater convenience and has the potential to lead to increased compliance with vaccine recommendations. This approach could benefit public health by synergistically increasing coverage rates against influenza and SARS-CoV-2 viruses. The company continues to target a potential initial regulatory approval for the combination vaccine in 2025," Moderna stated.

07:25 EDT Orchard Therapeutics announces multiple presentations at ESGCT 2023 - Orchard Therapeutics announced eight presentations from across its hematopoietic stem cell, HSC, gene therapy platform will be featured at the European Society of Gene and Cell Therapy, ESGCT, 30th Annual Congress taking place October 24-27, 2023, in Brussels. Featured presentations include a range of interim clinical outcomes in addition to the neurological and skeletal results previously reported from the company's proof-of-concept study of OTL-203 in the Hurler subtype of mucopolysaccharidosis type I, as well as well as a first look at pre-clinical data demonstrating the use of vectorized HSCs as a delivery vehicle for monoclonal antibodies. In addition, several abstracts from the company's pre-clinical research programs demonstrate the therapeutic potential of HSC gene therapy to address larger indications, including a genetic sub-type of frontotemporal dementia and Crohn's disease, as well as chronic autoimmune disorders. "Together with our clinical collaborators, we're proud of our significant presence at ESGCT which continues to underscore the transformative impact and broad applicability of our HSC gene therapy platform," said Fulvio Mavilio, Ph.D., chief scientific officer of Orchard Therapeutics. "Collectively, these data demonstrate the potential of our approach to correct the underlying genetic defects responsible for several difficult-to-treat diseases, furthering our efforts toward unlocking the full promise of our portfolio."

07:23 EDT Theratechnologies announces operational update - Theratechnologies announced further changes to its operations that will see a tapering of R&D activities, which necessitates a reduction of up to 25 positions. The Company expects to realize recurring yearly savings of approximately US$3.5 million resulting from this reorganization and will record a restructuring charge of approximately US$1.5 million in its fourth quarter of 2023. "The decision announced today was difficult to make, but it is aligned with our goal to build a profitable organization and deliver returns to our shareholders," said Paul Levesque, President and Chief Executive Officer, Theratechnologies. "We sincerely appreciate the contributions of those impacted, which indeed were instrumental in making Theratechnologies a better organization." The Company is committed to delivering on Part 3 of the Phase 1 clinical trial in advanced ovarian cancer for sudocetaxel zendusortide.

07:21 EDT XPO, Inc launches in-house, over-the-road operation to improve linehaul network - XPO is launching an in-house, over-the-road operation staffed exclusively by team drivers. The Road Flex program is part of the company's previously announced strategy to insource third-party linehaul carrier miles to drive greater efficiency, expected cost savings and better service for customers. The Road Flex program is already underway with sleeper team runs from bases in Dallas, Texas and Phoenix, Arizona. The company expects to expand this operation to a carefully selected group of additional service centers in 2024. Tim Staroba, president of the East Division at XPO, said, "The launch of the Road Flex operation is a key step in accelerating our plan to insource third-party linehaul miles and create greater efficiency in our network. It'll enable us both to reduce costs and improve service for our customers by minimizing freight re-handling and expediting deliveries. We look forward to the growth of this new program and the great team drivers who will be joining XPO to support it."

07:18 EDT Globus Medical presents five-year outcomes from Simplify Cervical Disc study - Globus Medical presented five-year outcomes from the NuVasive Simplify Cervical Disc study at the North American Spine Society, NASS, 38th Annual Meeting. The study demonstrates positive, long-term clinical outcomes, a high rate of overall composite success at 60 months, and statistical superiority to anterior cervical discectomy fusion, ACDF, procedural outcomes. "Having clinically backed, long-term data for the Simplify Cervical Disc validates the promising clinical data we saw Simplify having at the two-year mark," said Kyle Malone, senior vice president, Scientific Affairs of Globus Medical. "We will continue to innovate within the cervical spine segment providing industry-leading, procedural solutions clinically designed to deliver better outcomes for patients." The five-year Simplify Cervical Disc study found: Simplify Cervical Disc was statistically superior to the ACDF control in terms of overall composite success at five years, Statistically significant postoperative improvements in neck disability index and visual analog scale found at two years were maintained through five years, with the Simplify Cervical Disc group having significantly lower NDI and VAS scores at five years when compared to the ACDF control, Average disc height and flexion/extension range of motion increased postoperatively in the Simplify Disc group and remained above preoperative levels throughout follow-up, and No device failures were reported in the Simplify Disc group.

07:17 EDT AstraZeneca sBLA for Flumist Quadrivalent accepted for review by FDA - AstraZeneca's supplemental biologics license application, or sBLA, for the approval of a self- or caregiver-administered option for Flumist Quadrivalent, a needle-free nasal spray, has been accepted for review by the FDA. If approved, Flumist Quadrivalent will be the first flu vaccine available to be self-administered by eligible patients or administered by caregivers, adding an additional option to be vaccinated against influenza. The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer or administer Flumist Quadrivalent to eligible patients 2-49 years of age when given instructions for use without any additional guidance. Flumist Quadrivalent, which is sprayed into the nose, has extensive data demonstrating comparable effectiveness and acceptable safety relative to other flu vaccines. The Prescription Drug User Fee Act date is expected during the first quarter of 2024. If approved at that time, Flumist Quadrivalent is anticipated to be available for self-administration in the US for the 2024/2025 flu season.

07:16 EDT Spire Global awarded a subcontract by Riverside Research - Spire Global announced it was awarded a subcontract by Riverside Research, an advanced research nonprofit, to provide star tracker imagery as part of the Data Exploitation and Enhanced Processing for Space Domain Awareness project on behalf of the United States Space Force. The DEEP-SDA project aims to address the critical issue of space domain awareness by harnessing the power of existing star trackers and data to develop a software tool to enable the USSF to characterize and detect objects in low Earth orbit. Spire will be the leading provider of star tracker imagery, and all data will be used in direct support of the Joint Task Force-Space Defense Commercial Operations Cell, a specialized Space Force unit that works with commercial space data.

07:14 EDT Ginkgo Bioworks' partnership with Penn State University supported by USDA grant - Ginkgo Bioworks is joining efforts with Penn State University to integrate its biosurveillance capabilities into the university's research of 58 wildlife species for SARS-CoV-2 to monitor potential spillover to humans. The initiative is supported by a cooperative agreement awarded to Penn State from the U.S. Department of Agriculture Animal and Plant Health Inspection Service. In addition to potentially threatening human health, the virus's presence and past cross-species transmission has the potential to threaten certain agricultural species that are vital for the global food supply. The university's research on under-sampled species aims to bridge this surveillance gap by providing data that will allow more accurate and informed interventions to prevent the spread and impact of new SARS-CoV-2 variants. In partnering with Concentric by Ginkgo, the university will gain access to the biosurveillance research and analytics capabilities used by government institutions to help build more stable and robust biosecurity infrastructure.

07:13 EDT Syndax to submit NDA to FDA for revumenib - Syndax Pharmaceuticals announced that the company will submit a New Drug Application for revumenib in relapsed or refractory KMT2Ar acute leukemia, including acute myeloid leukemia and acute lymphoid leukemia, under the U.S. FDA Real-Time Oncology Review program. Revumenib is the company's highly selective oral menin inhibitor. During the Company's pre-NDA meeting, the FDA indicated that it would review the revumenib NDA submission for adult and pediatric KMT2Ar acute leukemia under the Oncology Center of Excellence RTOR Program. Inclusion in the RTOR program follows the previously announced FDA Breakthrough Therapy Designation for the same indication and recent positive topline data from the AUGMENT-101 pivotal trial in R/R KMT2Ar acute leukemia. Syndax plans to initiate the NDA submission imminently and expects to complete the submission by year-end 2023.

07:10 EDT Verizon reports Q3 broadband net additions of 434,000 - Total broadband net additions of 434,000, representing the fourth consecutive quarter that Verizon reported more than 400,000 broadband net additions. Total broadband net additions included 384,000 fixed wireless net additions, an increase of 42,000 fixed wireless net additions from third-quarter 2022. Verizon now has approximately 10.3 million total broadband subscribers, including nearly 2.7 million subscribers on its fixed wireless service.

07:08 EDT AerCap announces new lease agreement with Turkish Airlines - AerCap Holdings (AER) announced that it has reached agreement with Turkish Airlines for the lease of three new Boeing (BA) 787-9 aircraft and 25 new MAX-8 aircraft, and lease extensions for six used Airbus (EADSY) A330-200 aircraft. The new aircraft are scheduled to begin delivery in 2024 through 2026.

07:04 EDT Bristol Myers announces FDA Breakthrough Therapy Designation for BMS-986278 - Bristol Myers Squibb announced that the U.S. FDA has granted Breakthrough Therapy Designation for BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 antagonist, for the treatment of progressive pulmonary fibrosis, a devastating, life-threatening illness. Currently, there is only one therapy approved for the treatment of PPF.

06:54 EDT Moderna, Caris enter multi-year oncology and novel therapeutics agreement - Caris Life Sciences announced a new agreement with Moderna in support of Moderna's oncology and novel therapeutics initiatives. Through this multi-year agreement, Moderna will leverage Caris' vast library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing and protein analyses along with claims data to enhance development strategies for Moderna's oncology pipeline, including facilitation of optimal clinical trial design, discovery of novel biomarkers and characterization of resistance mechanisms.

06:47 EDT Halliburton CEO sees continued demand growth for oilfield services in 2024 - "Halliburton delivered an impressive third quarter and our margin strength demonstrated the power of our strategy. I am pleased with the stability of our North America business and the profitability of our International growth," commented Jeff Miller, Chairman, President and CEO. "Everything I see today strengthens my conviction in the long duration of this upcycle. Against this backdrop, we expect continued demand growth for oilfield services in 2024 and beyond. Halliburton delivered strong returns to our shareholders as demonstrated by more than $500 million of Free Cash Flow and repurchases of approximately $200 million of common stock and $150 million of debt during the quarter."

06:42 EDT General Motors reports Q3 total vehicle sales 981,000

06:38 EDT Terran Orbital selected by Lockheed Martin to build 36 satellite buses - Lockheed Martin (LMT) has awarded Terran Orbital (LLAP) a contract to build 36 satellite buses for Space Development Agency's Tranche 2 Transport Layer Beta constellation. Terran Orbital will deliver the buses to Lockheed Martin, which will conduct payload integration and jointly operate the satellites with SDA. SDA's T2TL Beta constellation will advance the Proliferated Warfighter Space Architecture's initial warfighting capability with targeted technology enhancements, mission-focused payload configurations, and increased integration. Terran Orbital is currently building 42 buses for Lockheed Martin to help the company fulfill its $700M contract for the SDA's Tranche 1 Transport Layer, currently scheduled for a late 2024 launch. The T2TL Beta satellites are scheduled to be deployed into low Earth orbit during a series of launches starting in 2026.

06:35 EDT PulteGroup reports debt-to-capital ratio reduced to 16.5% - Reports net debt-to-capital ratio of 1% including company's cash balance of $1.9B.

06:29 EDT Ceragon Networks to acquire Siku in transaction valued at $13M-$15M - Ceragon Networks announced that it has entered into a definitive agreement to acquire Siklu, a provider of multi-Gigabit "wireless fiber" connectivity in urban, suburban and rural areas, for an enterprise value of $13M-$15M. As consideration to Siklu's shareholders, Ceragon will issue approximately 1.5M ordinary shares. Ceragon is expected to assume financial liabilities of approximately $10M-$12M, of which approximately $2.5M are classified as long-term debt. Ceragon is expected to generate approximately $25M-$29M in incremental 2024 revenue from this acquisition. The acquisition is expected to be accretive to the consolidated gross margins of Ceragon as Siklu's margins are at levels significantly higher than Ceragon's historical margins. Ceragon management expects the combination to improve Siklu's results by leveraging Ceragon's working capital management capabilities, as well as expanded profitability following synergies. Inclusive of these business improvements, management anticipates the transaction to be accretive to non-GAAP earnings by the second half of 2024. As part of this transaction, Ceragon will expand its total loan credit facility by $5M to $77M total, and Siklu's primary lender will join Ceragon's lending consortium. Operating in the millimeter wave bands since 2008, Siklu's wireless solutions have been used by service providers, Private Networks and system integrators for many years for providing Wireless Transport and Access solutions. Siklu has deployed over 300,000 outdoor antenna units to date in over 50 countries. Siklu has been the leader in market share of E-band installations in the US for the last three years. The company has approximately 60 employees globally, including deep technical expertise in radio frequency communications and PtMP technology. Ceragon expects the deal to close by the end of 2023.

06:17 EDT Kemper sees 2024 ROE of 10% or greater

06:15 EDT Danaher sees FY23 base business core revenue down slightly - The company said, "For full year 2023, the Company anticipates that non-GAAP base business core revenue from continuing operations will be down slightly year-over-year."

06:13 EDT ZeroFox awarded expanded cybersecurity contract with U.S. federal agency - ZeroFox announced its continued partnership with a strategic U.S. federal agency focused on cybersecurity. This renewal marks the 9th continuous year of ZeroFox supporting critical cyber threat intelligence activities. The partnership originated between the agency and LookingGlass Cyber Solutions, which ZeroFox acquired in April earlier this year. This program supports thousands of users across more than 200 departments and agencies across federal, state, and local governments to provide cyber threat intelligence, attack surface Intelligence, and advanced security operations support.

06:08 EDT Spotify sees Q4 revenue EUR 3.7B - Assumes approximately 300 bps headwind to growth Y/Y due to foreign exchange rate movements. Sees Q4 total MAUs 601M; total premium subscribers 235M; gross margin 26.65; operating income EUR 37M.

06:06 EDT GE sees GE Aerospace, GE Vernova launching in 2Q24

06:03 EDT GE 'well positioned' to launch GE Aerospace, GE Vernova as independent companies